OncoMatch/Clinical Trials/NCT07264647
Neoadjuvant Chemo-immunotherapy for Stage III PD-L1 Positive Non-Small Cell Lung Cancer (NSCLC)
Is NCT07264647 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies Tislelizumab for stage iii nsclc.
Treatment: Tislelizumab — A Ph.2, single-arm, monocentric, trial of neo-adjiuvant chemo-immunotherapy for stage III, PD-L1 positive, NSCLC. Adults and smokers (past or current) diagnosed with stage III NSCLC without driver molecular alterations (EGFR, ALK, ROS1, RET).
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Cancer type
Non-Small Cell Lung Carcinoma
Biomarker criteria
Required: PD-L1 (CD274) TPS ≥ 1% (≥ 1%)
PD-L1 TPS ≥ 1% according to local testing
Required: EGFR wild-type
No evidence of EGFR mutations by local testing
Required: ALK wild-type
No evidence of ALK rearrangements by local testing
Required: ROS1 wild-type
No evidence of ROS1 rearrangements by local testing
Required: RET wild-type
No evidence of RET rearrangements by local testing
Disease stage
Required: Stage III
Excluded: Stage IV
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: any therapy for current lung cancer
Any previous therapy for current lung cancer, including chemotherapy or radiation therapy
Cannot have received: immune checkpoint inhibitor
Previous treatment with an antibody or drug against the immune checkpoint pathway, including but not limited to, therapeutic anti-cytotoxic T-lymphocyte antigen-4-associated antibodies (anti-CTLA-4), anti-PD-1 and anti-PD-L1
Lab requirements
Blood counts
Absolute neutrophil count ≥ 1.5 x 10^9 /L. Platelets ≥ 75 x 10^9 /L. Hemoglobin ≥ 90 g/L. Must not have required blood transfusion or growth factor support ≤ 14 days before sample collection at screening.
Kidney function
Estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2. For patients intended to receive cisplatin: creatinine clearance 60mL/min. For patients intended to receive carboplatin: creatinine clearance 45mL/min.
Liver function
Serum total bilirubin ≤ 1.5 x ULN (total bilirubin must be < 3 x ULN for patients with Gilberts syndrome). AST and ALT ≤ 2.5 x ULN.
Adequate organ function as indicated by the following laboratory values obtained ≤ 14 days before the first dose of study drug: Patients must not have required blood transfusion or growth factor support ≤ 14 days before sample collection at screening for the following: Absolute neutrophil count ≥ 1.5 x 109 /L Platelets ≥ 75 x 109 /L Hemoglobin ≥ 90 g/L Estimated glomerular filtration rate ≥ 45 mL/min/1.73 m2 by Chronic Kidney Disease Epidemiology Collaboration equation. For patients intended to receive cisplatin: creatinine clearance 60mL/min For patients intended to receive carboplatin: creatinine clearance 45mL/min Serum total bilirubin ≤ 1.5 x upper limit of normal (ULN) (total bilirubin must be < 3 x ULN for patients with Gilberts syndrome). AST and ALT ≤ 2.5 x ULN For patients not receiving therapeutic anticoagulation: international normalized ratio or activated partial thromboplastin time 1.5ULN
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07264647 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Does this trial require CD274?
Yes, CD274 TPS ≥ 1% is a required biomarker for enrollment.
Does this trial require EGFR?
Yes, EGFR wild-type is a required biomarker for enrollment.
Does this trial require ALK?
Yes, ALK wild-type is a required biomarker for enrollment.
What disease stage is eligible?
Stage III is required.
Is there an age limit?
Yes. Patients must be 99 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify